ArticlePediatric blood & cancer2023
Children's Oncology Group's 2023 blueprint for research: Renal tumors.
Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.JCO precision oncology · 2026Pooled it
- Outcomes of robotic-assisted surgery for pediatric renal tumors: a systematic review.Journal of robotic surgery · 2025Pooled it
- Long-term adverse effects of modern Wilms tumour therapies: implications for monitoring.Nature reviews. Urology · 2026Review
- Article
- Tumor size predicts metastatic disease at diagnosis and prognosis in unilateral Wilms tumor: a population based study with external validation.Discover oncology · 2026Article
- Wilms Tumor with Inferior Vena Cava Thrombus: Comparative Analysis of Clinical Characteristics and Outcomes.Current oncology (Toronto, Ont.) · 2026Article
- Review
- Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney.Frontiers in pediatrics · 2026Review
- Primary Renal Mesenchymal Tumors: A Study from North India, Emphasizing Rare Entities and Molecular Profiles.Journal of kidney cancer and VHL · 2026Article
- Renal sarcomas in children and adolescents: a retrospective, multicenter cohort study.EClinicalMedicine · 2026Article
- Fluorescence-Guided Surgery in Pediatric Oncology: Current Practice and Future Directions.Cancers · 2025Review
- The effect of neighborhood deprivation on access to surgical care for pediatric renal tumors.Pediatric surgery international · 2025Article
- Prognostic factors for long-term survival in Wilms tumor: a retrospective study.BMC pediatrics · 2025Article
- Updated favourable-histology Wilms tumour risk stratification: rationale for future Children's Oncology Group clinical trials.Nature reviews. Urology · 2025Review
- Analysis of prognostic factors and development of a predictive model following radical nephrectomy for Wilms tumor in children.Oncology letters · 2025Article
- Exploring theFrontiers in physiology · 2025Article
- Development of a Multilayered Prognostic Model for Wilms' Tumor Based on Characteristic Lymphocyte Genes.Genetics research · 2025Article
- A novel nephrometry scoring system outperforms RENAL score, PADUA score, and SPARE score for feasibility prediction of nephron-sparing surgery in children with bilateral Wilms tumor.Quantitative imaging in medicine and surgery · 2024Article
- Robot-assisted resection of renal tumor in children and comparison with laparoscopic surgery.BMC surgery · 2024Article
- The impact of the route to diagnosis in nephroblastoma.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
Every year, approximately 600 infants, children, and adolescents are diagnosed with renal cancer in the United States. In addition to Wilms tumor (WT), which accounts for about 80% of all pediatric renal cancers, clear cell sarcoma of the kidney, renal cell carcinoma, malignant rhabdoid tumor, as well as more rare cancers (other sarcomas, rare carcinomas, lymphoma) and benign tumors can originate within the kidney. WT itself can be divided into favorable histology (FHWT), with a 5-year overall survival (OS) exceeding 90%, and anaplastic histology, with 4-year OS of 73.7%. Outcomes of the other pediatric renal cancers include clear cell sarcoma (5-year OS: 90%), malignant rhabdoid tumor (5-year OS: 10% for stages 3 and 4), and renal cell carcinoma (4-year OS: 84.8%). Recent clinical trials have identified novel biological prognostic markers for FHWT, and a series of Children's Oncology Group (COG) trials have demonstrated improving outcomes with therapy modification, and opportunities for further care refinement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.